How has post-implementation surveillance of high-coverage vaccination with HPV16/18-AS04 vaccine in England added to evidence about its cross-protective effects?
Surveillance of type-specific infections in vaccine-eligible populations in England has generated clear evidence of cross-protective effects from HPV16/18-AS04 vaccination against high-risk HPV 31/33/45 infections, consistent with other post-implementation observations and confirming and in some ways exceeding expectations from clinical trials.
Authors
- Marta Checchi (ORCID: https://orcid.org/0000-0003-1398-9017)
- Kavita Panwar (ORCID: https://orcid.org/0000-0002-1052-4698)
- Simon Beddows (ORCID: https://orcid.org/0000-0002-6879-6215)
- Anja Anderson (ORCID: https://orcid.org/0009-0007-1206-4190)
- Bernd Benninghoff (ORCID: https://orcid.org/0000-0003-1264-7074)
- Vincent Weynants (ORCID: https://orcid.org/0000-0002-6163-4838)
- Adoración Navarro-Torné (ORCID: https://orcid.org/0000-0002-1644-2415)
- Emmanuelle Ghys (ORCID: https://orcid.org/0000-0002-2345-3470)
Institutions
- Department of Health and Social Care (GB)
- Animal and Plant Health Agency (GB)
- Environment Agency (GB)
- GlaxoSmithKline (Belgium) (BE)
- GlaxoSmithKline (Switzerland) (CH)
- GlaxoSmithKline (Spain) (ES)
Publication Details
- Journal
- Vaccine
- Published
- 2024-08-29
- DOI
- https://doi.org/10.1016/j.vaccine.2024.126215
- Citations
- 4
- Primary Topic
- Cervical Cancer and HPV Research
- Type
- article
- Field-Weighted Citation Impact
- 1.55
Funders
- GlaxoSmithKline España